Edition:
United Kingdom

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

67.34EUR
22 Jun 2018
Change (% chg)

€0.22 (+0.33%)
Prev Close
€67.12
Open
€66.94
Day's High
€67.44
Day's Low
€66.80
Volume
298,992
Avg. Vol
339,505
52-wk High
€71.28
52-wk Low
€56.55

Latest Key Developments (Source: Significant Developments)

UCB Announces Briviact® (Brivaracetam) Now Approved By FDA To Treat Partial-Onset (Focal) Seizures In Pediatric Epilepsy Patients
Monday, 14 May 2018 

Ucb SA ::UCB ANNOUNCES BRIVIACT® (BRIVARACETAM) NOW APPROVED BY FDA TO TREAT PARTIAL-ONSET (FOCAL) SEIZURES IN PEDIATRIC EPILEPSY PATIENTS.  Full Article

UCB Announces Positive CHMP Opinion For Cimzia®
Friday, 27 Apr 2018 

April 27 (Reuters) - UCB SA ::UCB ANNOUNCES POSITIVE CHMP OPINION FOR CIMZIA® (CERTOLIZUMAB PEGOL) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS.EUROPEAN COMMISSION’S ENDORSEMENT OF CHMP POSITIVE OPINION FOR PSORIASIS EXPECTED IN Q2.CHMP POSITIVE OPINION IS BASED ON DATA FROM A PHASE 3 CLINICAL DEVELOPMENT PROGRAM CONSISTING OF CIMPASI-1, CIMPASI-2 AND CIMPACT.THIS WOULD FURTHER BROADEN CLINICAL VALUE OF CIMZIA.  Full Article

UCB Q1 Revenue Down At 1.07 Billion Euros
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Ucb SA ::Q1 REVENUE REACHED € 1.07 BILLION: -5%, -1% CER;.FINANCIAL OUTLOOK 2018 CONFIRMED: REVENUE EXPECTED TO REACH € 4.5 - 4.6 BILLION.FINANCIAL OUTLOOK 2018 CONFIRMED: RECURRING EBITDA SHOULD REACH € 1.3 - 1.4 BILLION.Q1 VIMPAT SALES EUR 242 MILLION VERSUS EUR 239 MILLION YEAR AGO.Q1 NEUPRO SALES EUR 71 MILLION VERSUS EUR 74 MILLION YEAR AGO.Q1 KEPPRA SALES EUR 189 MILLION VERSUS EUR 210 MILLION YEAR AGO.Q1 REVENUE EUR 1.07 BILLION VERSUS EUR 1.12 BILLION YEAR AGO.Q1 CIMZIA SALES EUR 310 MILLION VERSUS EUR 317 MILLION YEAR AGO.CORE EARNINGS PER SHARE ARE EXPECTED IN THE RANGE OF € 4.30 – 4.70 IN 2018.  Full Article

UCB Acquires Midazolam Nasal Spray From Proximagen
Friday, 20 Apr 2018 

April 20 (Reuters) - UCB SA UCB.BR::UCB TO EXPAND EPILEPSY PORTFOLIO WITH STRATEGIC ACQUISITION OF MIDAZOLAM NASAL SPRAY FROM PROXIMAGEN.UCB WILL MAKE AN UPFRONT CASH PAYMENT OF $150 MILLION.MIDAZOLAM NASAL SPRAY (USL261) COMPLETED PHASE 3 CLINICAL DEVELOPMENT AND IS READY TO BE FILED AS A NEW DRUG APPLICATION (NDA) IN 2018.IN ADDITION, PROXIMAGEN IS ELIGIBLE TO RECEIVE CONTINGENT PAYMENTS OF UP TO $220 MILLION BASED ON CERTAIN REGULATORY APPROVAL AND SALES-BASED MILESTONES.TRANSACTION IS EXPECTED TO CLOSE IN Q2 OF 2018.USL261 ALREADY GRANTED ORPHAN DRUG AND FAST TRACK DESIGNATION BY US FDA.  Full Article

UCB Acquires Element Genomics
Thursday, 5 Apr 2018 

April 5 (Reuters) - UCB SA ::UCB STRENGTHENS RESEARCH CAPABILITIES WITH ACQUISITION OF ELEMENT GENOMICS, A DUKE UNIVERSITY BIOTECH SPIN-OFF.‍TOTAL COST OF TRANSACTION WILL AMOUNT TO UP TO USD 30 MILLION​.‍ELEMENT GENOMICS' TEAM WILL CONTINUE TO BE BASED IN DOWNTOWN DURHAM, WILL WORK CLOSELY WITH UCB'S RESEARCH TEAMS​.  Full Article

UCB Announces That EMA Has Approved Label Change For Cimzia
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - UCB SA ::EMA HAS APPROVED LABEL CHANGE FOR UCB’S CIMZIA.LABEL CHANGE MAKING IT FIRST ANTI-TNF FOR POTENTIAL USE IN WOMEN WITH CHRONIC RHEUMATIC DISEASE, DURING PREGNANCY AND BREASTFEEDING.  Full Article

UCB Announces Positive Top Line Results Of Phase 2b Bimekizumab Study
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - UCB SA ::BIMEKIZUMAB DEMONSTRATES IMPRESSIVE JOINT AND SKIN RESPONSES FOR PSORIATIC ARTHRITIS PATIENTS‍​.ANNOUNCES PHASE 2B BE ACTIVE STUDY MET THE PRIMARY OBJECTIVE OF ESTABLISHING DOSE RESPONSE FOR BIMEKIZUMAB WITH STATISTICAL SIGNIFICANCE.  Full Article

UCB Bimekizumab Announces Results For Phase 2b Of BE Agile Study ‍​
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - UCB SA ::BIMEKIZUMAB ADVANCES WITH SIGNIFICANT RESULTS IN ANKYLOSING SPONDYLITIS PATIENTS‍​.POSITIVE FIRST RESULTS IN ANKYLOSING SPONDYLITIS FROM PHASE 2B BE AGILE STUDY OF BIMEKIZUMAB SHOW STATISTICAL SIGNIFICANCE IN MULTIPLE DOSE GROUPS.BIMEKIZUMAB WAS GENERALLY WELL TOLERATED AND NO UNEXPECTED SAFETY SIGNALS WERE OBSERVED.THE STUDY ACHIEVED THE PRIMARY ENDPOINT (ASAS40)‍​.RESULTS FROM THIRD PHASE 2B STUDY OF BIMEKIZUMAB IN PSORIATIC ARTHRITIS EXPECTED SOON.UP TO 47% OF PATIENTS ACHIEVE AT LEAST 40% IMPROVEMENT VERSUS 13% OF PATIENTS RECEIVING PLACEBO, AT WEEK 12 ‍​.  Full Article

Dermira and UCB agree to end collaboration agreement for Cimzia
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Dermira Inc :Dermira and UCB agree to end collaboration agreement for Cimzia.Dermira Inc - ‍Dermira to transition development and commercialization responsibility for Cimzia (Certolizumab Pegol) in psoriasis back to UCB​.Dermira Inc - ‍collaboration agreement will terminate on February 15, 2018 and companies anticipate completion of transition by such date​.Dermira Inc - ‍pursuant to collaboration agreement, there are no termination or penalty payments required by either party​.Dermira - for repurchase of all product rights, licenses and intellectual property relating to cimzia, ucb will pay to dermira $11.0 million by Nov 13.  Full Article

UCB 9-month revenue up at 3.3 billion euros, 2017 outlook increased
Friday, 20 Oct 2017 

Oct 20 (Reuters) - UCB SA ::9-MONTH REVENUE INCREASED TO € 3.3 BILLION, BY 9%; MAIN PRODUCTS GREW BY 15% TO € 2.6 BILLION .9-MONTH NEUPRO REVENUE EUR 230 MILLION VERSUS EUR 217 MILLION YEAR AGO‍​.9M VIMPAT REVENUE EUR 707‍​ MILLION VERSUS EUR 586 MILLION YEAR AGO.9M KEPPRA REVENUE EUR 607‍​ MILLION VERSUS EUR 538 MILLION YEAR AGO.9M IMMUNOLOGY/CIMZIA REVENUE EUR ‍​1.02 BILLION VERSUS EUR 927 MILLION YEAR AGO.9-MONTH NEUPRO REVENUE EUR 230 MILLION VERSUS EUR 217 MILLION YEAR AGO.9-MONTH BRIVIACT REVENUE EUR 57 MILLION VERSUS EUR 11 MILLION YEAR AGO.FINANCIAL OUTLOOK 2017 INCREASED: NOW REVENUE EXPECTED BETWEEN €4.4 - 4.5BN. REBITDA BETWEEN €1.25 - 1.35BN‍​.9M NEUROLOGY REVENUE EUR ‍​ 1.60 BILLION VERSUS EUR 1.35 BILLION YEAR AGO.FINANCIAL OUTLOOK 2017 INCREASED: NOW EXPECTED CORE EPS BETWEEN €4.10 – 4.50.BRIVIACT APPROVED AS MONOTHERAPY IN THE U.S.‍​.VIMPAT APPROVED AS MONOTHERAPY IN JAPAN AND FOR CHILDREN AS ADD-ON THERAPY IN THE EU. ‍​.  Full Article

French and Benelux stocks-Factors to watch on June 4

June 4 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.